Increase/Decrease in Cash: The total change in cash for the company over the given period.
Larimar Therapeutics, Inc. (LRMR) had Increase/Decrease in Cash of $56.92M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-47.71M |
|
-- |
|
-- |
|
$49.50M |
|
$-49.50M |
|
$1.79M |
|
$-47.71M |
|
$-47.71M |
|
$-47.71M |
|
$-47.71M |
|
$-47.71M |
|
$-47.71M |
|
$-49.50M |
|
$-49.74M |
|
78.32M |
|
78.32M |
|
$-0.61 |
|
$-0.61 |
|
| Balance Sheet Financials | |
$183.22M |
|
$0.71M |
|
$4.13M |
|
$187.35M |
|
$45.12M |
|
-- |
|
$3.20M |
|
$48.31M |
|
$139.04M |
|
$139.04M |
|
$139.04M |
|
85.59M |
|
| Cash Flow Statement Financials | |
$-74.67M |
|
$66.31M |
|
$65.29M |
|
$33.82M |
|
$90.75M |
|
|
Increase/Decrease in Cash |
$56.92M |
$5.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-74.77M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-34.32% |
|
-34.32% |
|
-25.47% |
|
-34.32% |
|
$1.62 |
|
$-0.95 |
|
$-0.95 |
|